Labiotech.eu

News and Trends 25 Jul 2023

Crescendo Biologics raises $32M and expands cancer trial

Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major […]

July 25, 2023 - 2 minutesmins - By Jim Cornall

In Depth 24 Jul 2023

Sarcoma research: is a breakthrough in sight?

Among the rarest forms of cancers, sarcomas develop in the bones and connective tissues that support structures in the body like blood vessels, nerves and joints. This year, around 13,400 new cases of soft tissue sarcomas are estimated to be diagnosed in the U.S. alone, according to the American Cancer Society. As July marks Sarcoma […]

July 24, 2023 - 7 minutesmins - By Roohi Mariam Peter

In Depth 21 Jul 2023

How AI is shaping clinical research and trials

Artificial intelligence (AI) is everywhere at the minute, seemingly being used in some capacity in almost every professional industry, including clinical research and trials. In fact, it is fair to say that AI has taken the biotech industry by storm, and the hype surrounding it has led to numerous AI startup companies coming onto the […]

July 21, 2023 - 7 minutesmins - By Willow Shah-Neville

Podcast 20 Jul 2023

Beyond Biotech podcast 55: Inflammasomes

This week on our podcast, we’re talking about inflammasome inhibitors with Alan Watt, CEO of NodThera. The company recently announced it is the first to show a reduction in neuroinflammation with an inflammasome inhibitor. NodThera announced positive initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects […]

July 20, 2023

News and Trends 20 Jul 2023

CatalYm shows importance of GDF-15 in tumor immunotherapy resistance

CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […]

July 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Endometrial cancer drug receives breakthrough therapy designation in China

HUTCHMED (China) Limited has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based […]

July 20, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Mage Biologics created to develop oral antibody therapy for ulcerative colitis

TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will invest with its TVM Life Science Innovation II SCSp (TVM LSI II) fund and will provide strategic advice to Mage Bio. Mage Bio is the […]

July 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Seven pharma companies form alliance to prepare for future pandemics

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

July 20, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Biomica announces interim positive results from irritable bowel syndrome program

Biomica Ltd., a clinical-stage biopharmaceutical company developing microbiome-based therapeutics, has released interim positive results from pre-clinical studies in its irritable bowel syndrome (IBS) program. The work was performed in collaboration with the lab of Kara Gross Margolis, associate director for clinical and translational research for the New York University Pain Research Center and an associate […]

July 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jul 2023

Sosei Heptares hails ‘transformational’ acquisition

Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd (IPJ) and Idorsia Pharmaceuticals Korea Co., Ltd (IPK). The strategic transaction also includes the Japan and APAC territory rights, with the exception of China, to a pipeline of medicines from Idorsia’s portfolio, with lead product PIVLAZ (clazosentan) already commercially available and […]

July 20, 2023 - 5 minutesmins - By Jim Cornall

In Depth 19 Jul 2023

Genetic engineering giants: is China poised to lead the way?

For many people, when they hear China and genetic engineering in the same sentence, it is often synonymous with scandal, and gene-edited babies may spring to mind. And, although it is true that nearly five years ago, researcher He Jiankui infamously claimed he had created the first ever gene-edited babies, before going to prison for […]

July 19, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 19 Jul 2023

Novel bacterial communication system could help take on antimicrobial resistance

A new stress signaling system enables bacteria cells to adapt and protect themselves against the immune system and certain antibiotics. The discovery was made by researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for Environmental […]

July 19, 2023 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Crescendo Biologics raises $32M and expands cancer trial

Sarcoma research: is a breakthrough in sight?

How AI is shaping clinical research and trials

Beyond Biotech podcast 55: Inflammasomes

CatalYm shows importance of GDF-15 in tumor immunotherapy resistance

Endometrial cancer drug receives breakthrough therapy designation in China

Mage Biologics created to develop oral antibody therapy for ulcerative colitis

Seven pharma companies form alliance to prepare for future pandemics

Biomica announces interim positive results from irritable bowel syndrome program

Sosei Heptares hails ‘transformational’ acquisition

Genetic engineering giants: is China poised to lead the way?

Novel bacterial communication system could help take on antimicrobial resistance

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!